Back to results
US 2003/0149060 A1Published application
A2A adenosine receptor antagonists
AssigneeCV Therapeutics, Inc.
InventorGloria Cristalli
Life of this patent
Estimating the term…
Abstract
Disclosed are novel A2A adenosine receptor antagonists, useful for treating various disease states, for example cardiovascular disorders, including tissue damage due to ischemia, CNS diseases, including Parkinson's disease, depression, and the like.
Claims25
A compound of the Formula I:
- 11
- wherein:
- R1 is optionally substituted aryl or optionally substituted heteroaryl;
- R2 is optionally substituted lower alkyl or optionally substituted cycloalkyl;
- R3 is halogen, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
- with the proviso that R3 cannot be pyrazolyl;
- X is —O—, —S—, or —NH—;
- and
- Y is optionally substituted alkylene;
- with the proviso that R3 cannot be pyrazolyl;
- and with the proviso that when X is —NH— and Y is —CH2—, R1 is not dihydroxyphenyl.
8 more elements
A method of treating a disease state in a mammal that is alleviable by treatment with an A2A adenosine receptor antagonist, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the Formula I:
- 12
- wherein:
- R1 is optionally substituted aryl or optionally substituted heteroaryl;
- R2 is optionally substituted lower alkyl or optionally substituted cycloalkyl;
- R3 is hydrogen, halogen, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;
- with the proviso that R3 cannot be pyrazolyl;
- X is —O—, —S—, or —NH—;
- and
- Y is optionally substituted alkylene.
6 more elements
Dependencies are inferred from the claim text.